PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
56 hedge funds and large institutions have $38.9M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 6 closing their positions.
743% more call options, than puts
Call options by funds: $118K | Put options by funds: $14K
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
10% more funds holding
Funds holding: 51 → 56 (+5)
24% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 17
47% less capital invested
Capital invested by funds: $73.4M → $38.9M (-$34.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCM
MAI Capital Management
Independence,
Ohio
|
+$2.3M |
| 2 |
TCM
Towercrest Capital Management
Newtown,
Pennsylvania
|
+$1.71M |
| 3 |
VPW
Vericrest Private Wealth
Newtown,
Pennsylvania
|
+$1.71M |
| 4 |
Renaissance Technologies
New York
|
+$145K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$65.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$1.94M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.03M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$443K |
| 4 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$398K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$228K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Simplex Trading
Chicago,
Illinois
| $1K | -$17.5K | -10,798 | -92% |
|
|
CG
52
Cutler Group
San Francisco,
California
| $1K | – | – | – |
|
53
BNP Paribas Financial Markets
Paris,
France
| $104 | – | – | – |
|
|
ECM
54
ExodusPoint Capital Management
New York
| – | -$1.03M | -394,211 | Closed |
|
|
55
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$443K | -273,100 | Closed |
|
56
Citadel Advisors
Miami,
Florida
| – | -$98K | -37,452 | Closed |
|
|
XT
57
XTX Topco
George Town,
Cayman Islands
| – | -$41K | -15,574 | Closed |
|
58
D.E. Shaw & Co
New York
| – | -$31K | -11,796 | Closed |
|
|
SIG
59
Sargent Investment Group
Bethesda,
Maryland
| – | -$30K | -11,675 | Closed |
|
60
Bank of America
Charlotte,
North Carolina
| – | -$483 | -298 | -100% |
|
|
TRCT
61
Tower Research Capital (TRC)
New York
| – | +$232 | +143 | +130% |
|
PHAS Hedge Fund Activity: Q1 2022 in Review
56 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q1 2022, worth a combined $38.9M — down 47% from $73.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PHAS positions and 6 closed out — a net gain of 5 holders — while 13 added to existing stakes and 17 trimmed.
The largest buyer was MAI Capital Management, opening a new position worth an estimated $2.3M. The largest seller was Wellington Management Group, cutting an estimated $1.94M.
- 56 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q1 2022, up from 51 in Q4 2021.
- Funds reported $38.9M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 47% quarter-over-quarter.
- 11 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 6 closed out, a net change of +5 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was MAI Capital Management, an estimated $2.3M added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Wellington Management Group, an estimated $1.94M sold.
Based on aggregated 13F filings for Q1 2022.